Thanks for this. I read a preprint about that, and I have mixed feelings regarding what I think of it. They didn't control for prior infection in the unvaccinated group, but then, if that was going to affect effectiveness numbers, it should affect the numbers for Moderna and Pfizer equally, so I'm not sure that invalidates the higher findings for Moderna. Still, I'd like to see more info on the distribution of those who received Moderna vs. Pfizer. For example, were more of the Pfizer folks in areas with higher or more sustained transmission (which means there would be a higher rate of breakthrough infections because there are more opportunities to infect), or were the vaccinated people in both the Pfizer and Moderna groups from areas with similar levels and durations of transmission? That's the biggest question I have, and I didn't see it addressed in the preprint. Perhaps it will be addressed in an update or when it's fully published after peer-review. I think it's reasonable, though, if you have access to Moderna, get Moderna. If you have to wait to get Moderna and can get Pfizer now, get the Pfizer now, I think.